Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody.
The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 25 | -0.80 | -1.03 Increased by +22.33% |
| Feb 26, 25 | -1.26 | -1.02 Decreased by -23.56% |
| Nov 12, 24 | -5.02 | -9.30 Increased by +46.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 10.00 M Increased by +N/A% | -33.57 M Decreased by -20.77% | Decreased by -335.73% Decreased by N/A% |
| Dec 31, 24 | 5.00 M Increased by +N/A% | -52.60 M Decreased by -113.95% | Decreased by -1.05 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -38.61 M Decreased by -208.42% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -37.98 M Decreased by -30.74% | Decreased by N/A% - |
| Mar 31, 24 | 0.00 Decreased by N/A% | -27.80 M Decreased by -45.57% | Decreased by N/A% - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -24.59 M Decreased by -29.45% | Decreased by N/A% - |
| Sep 30, 23 | 50.00 M - | 35.61 M - | Increased by +71.22% - |
| Jun 30, 23 | N/A - | -29.05 M - | - - |